A Blood Test for Dementia? A Cohort Study to Assess the Diagnostic Utility of Plasma Neurofilament Light Chain Protein in All-cause Dementia

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests. Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months. Individuals at risk of a Fronto-temporal dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• All patients presenting to Eastern Health services with a cognitive complaint or potential neurodegenerative disorder

Locations
Other Locations
Australia
Box Hill Hospital
RECRUITING
Box Hill
Wantirna Health
RECRUITING
Wantirna
Contact Information
Primary
Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN
amy.brodtmann@monash.edu
03 9094 9540
Backup
Svetlana Ivanic, BSc(Hons)
svetlana.ivanic@monash.edu
Time Frame
Start Date: 2021-08-01
Estimated Completion Date: 2027-12
Participants
Target number of participants: 1000
Related Therapeutic Areas
Sponsors
Leads: Monash University
Collaborators: The Florey Institute of Neuroscience and Mental Health, Eastern Health, Invitae Corporation, Wake Forest University, Redenlab, Deakin University, University of Melbourne

This content was sourced from clinicaltrials.gov